-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-01 in Empyema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-01 in Empyema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-01 in Empyema Drug Details: LTI-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-03 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-03 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-03 in Idiopathic Pulmonary Fibrosis Drug Details: LTI-03 is under development...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pleural Effusion – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleural Effusion - Drugs In Development, 2023’, provides an overview of the Pleural Effusion pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Pleural Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleural Disease - Drugs In Development, 2023’, provides an overview of the Pleural Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleural Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: Aileron Therapeutics Inc’s Sulanemadlin
Empower your strategies with our Net Present Value Model: Aileron Therapeutics Inc's Sulanemadlin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Profile
Aileron Therapeutics Inc – Company Profile
Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company. The company develops medicines to make chemotherapy safer and thereby more effective to save more patients’ lives. Its products include ALRN-6924 MDM2 and MDMX dual inhibitor a chemoprotective agent that treats patients with p53-mutated cancers. It also provides radioprotection, anti-cancer research and discovery research. The company partners with research organizations to provide its products. Aileron Therapeutics is headquartered in Boston, Massachusetts, the US.
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Merkel Cell Carcinoma Pipeline Drugs Market Report Overview Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Symptom includes painless nodule on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery. The Merkel Cell Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Merkel Cell...